# Oxygen Therapy and Respiratory Care Devices Market

> Global Oxygen Therapy and Respiratory Care Devices Market Research Report By Product, By Type, By Technology, By Device Portability, By Indication, By End User and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast Till 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 11.17%
- **2025:** USD 37.57 Billion
- **2035:** USD 74.42 Billion
- **Key Players:** ResMed, Koninklijke Philips N.V., Medtronic, GE Healthcare, Drägerwerk AG & Co. KGaA, Getinge, Inogen, Inc., CAIRE Inc.

**Report ID:** MRFR/MED/66596-CR · **Pages:** 200 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** August 26, 2026

**URL:** https://www.marketresearchfuture.com/reports/oxygen-therapy-and-respiratory-care-devices-market-68396

---

## Market Summary

## Oxygen Therapy and Respiratory Care Devices Market Summary

The global oxygen therapy and [respiratory care devices](https://www.marketresearchfuture.com/reports/respiratory-care-devices-market-6517) market was valued at USD 37.57 billion in 2025 and is projected to reach USD 74.42 billion by 2035, expanding at a compound annual growth rate (CAGR) of 7.09% during the 2026–2035 forecast period. Growth is underpinned by several converging structural forces: the rising global prevalence of chronic obstructive pulmonary disease (COPD), asthma, and pulmonary fibrosis is driving sustained demand for supplemental oxygen and automated respiratory support systems. Concurrently, the aging population across developed economies is amplifying the need for long-term oxygen therapy and home-based respiratory care solutions. Technological advancements in automated breathing devices — including smart ventilation platforms, AI-integrated monitoring, and portable oxygen concentrator systems — are further accelerating market expansion by improving clinical outcomes and patient adherence. The expansion of hospital and critical-care capacity, particularly in intensive care unit (ICU) settings, adds a significant institutional demand layer that complements the growing home healthcare segment.

From a product and technology standpoint, respiratory care devices constitute the dominant product category with a 2025 market size of USD 22,518.20 million, reflecting the breadth of ventilators, CPAP/BiPAP devices, nebulizers, humidifiers, respiratory monitoring devices, and [airway management](https://www.marketresearchfuture.com/reports/airway-management-market-8472) solutions within this segment. Respiratory monitoring devices alone account for USD 12,198.77 million in 2025, underscoring the clinical emphasis on continuous patient surveillance. The fastest-growing product type is intelligent oxygen delivery systems, which, although relatively nascent at USD 79.73 million in 2025, are expanding at a remarkable CAGR of 14.67%, signaling a paradigm shift toward closed-loop, AI-enabled respiratory management. AI-enabled technology platforms as a whole are growing at 11.17% CAGR. Key commercial milestones include Getinge's expansion of its Servo-c ventilator portfolio with neonatal capabilities, broadening the addressable patient population from premature infants to adults, and Inogen's launch of the Voxi 5 stationary oxygen concentrator to improve long-term care access across the United States.

Regionally, Europe oxygen therapy and respiratory care devices market is the dominant market with a 2025 revenue of USD 11,498.64 million, driven by well-established reimbursement frameworks, high per-capita healthcare expenditure, and a large elderly population base. North America, valued at USD 15,263.19 million in 2025, is the fastest-growing region with a CAGR of 6.05%, propelled by robust adoption of portable and home-care oxygen systems and expanding telehealth integration. Asia-Pacific represents the highest growth trajectory at a 9.21% CAGR, fueled by rising healthcare infrastructure investment, urbanization-linked respiratory disease burden, and expanding insurance coverage in China, India, and Southeast Asian markets. The market outlook through 2035 remains strongly positive, driven by the convergence of demographic aging, chronic disease burden escalation, and the continued digitalization of respiratory care delivery.

## Key Report Takeaways

| Segment Dimension | Key Metric | Notes |
| --- | --- | --- |
| Product — Dominant | Respiratory Care Devices: USD 22,518.20 Mn (2025) | Largest product category, encompassing ventilators, monitoring, CPAP, nebulizers |
| Product — Fastest Growing | Respiratory Care Devices: 7.73% CAGR | Driven by ventilator upgrades and respiratory monitoring adoption |
| Type — Dominant | Respiratory Monitoring Devices: USD 12,198.77 Mn (2025) | Reflects emphasis on continuous patient surveillance in ICU and home settings |
| Type — Fastest Growing | Intelligent Oxygen Delivery Systems: 14.67% CAGR | Emerging segment with highest growth potential across all device types |
| Technology — Dominant | Continuous Flow: USD 23,785.52 Mn (2025) | Established delivery modality for institutional and home oxygen therapy |
| Technology — Fastest Growing | AI-enabled: 11.17% CAGR | Reflects rapid integration of artificial intelligence in respiratory device platforms |
| Device Portability — Dominant | Stationary: USD 22,802.62 Mn (2025) | Institutional demand anchors stationary device revenue |
| Device Portability — Fastest Growing | Portable: 8.13% CAGR | Home care and ambulatory trends driving portable device adoption |
| Indication — Dominant | COPD: USD 11,634.62 Mn (2025) | Largest therapeutic indication by revenue |
| Indication — Fastest Growing | Obstructive Sleep Apnea (OSA): 8.42% CAGR | Rising diagnosis rates and CPAP/BiPAP adoption fueling growth |
| End User — Dominant | Hospitals: USD 18,460.50 Mn (2025) | Primary care setting for acute and chronic respiratory management |
| End User — Fastest Growing | Long-term Care Facilities: 9.58% CAGR | Aging population driving institutional long-term respiratory care demand |
| Region — Dominant | Europe: USD 11,498.64 Mn (2025) | Mature reimbursement systems and high healthcare expenditure |
| Region — Fastest Growing | Asia-Pacific: 9.21% CAGR | Infrastructure expansion and rising chronic respiratory disease burden |

## Market Size and Forecast (2019–2035)

MRFR's market sizing methodology combines bottom-up revenue estimation from company filings, product-level shipment data, and regional reimbursement analysis with top-down demand modeling based on disease prevalence, healthcare infrastructure capacity, and demographic projections. Forecast values for 2026–2035 are derived using a constant CAGR of 7.09% applied to the validated 2025 base year estimate, cross-referenced against supply-side capacity additions and regulatory pipeline assessments. Historical values (2019–2024) reflect reported and estimated actual market performance.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Technological advancements in automated breathing devices (smart ventilation, AI integration, portable systems, monitoring, and safety features) | ~30% | Global, led by North America and Europe | Medium-to-Long-term | [6] |
| Aging population increasing demand for long-term oxygen therapy and home respiratory care | ~28% | Europe, North America, Asia-Pacific (Japan) | Long-term | [11] |
| Growth in hospital and critical-care capacity and ICU utilization requiring supplemental oxygen and automated respiratory support systems | ~22% | Asia-Pacific, Middle East & Africa | Short-to-Medium-term | [9] |
| Rising prevalence of respiratory diseases (COPD, asthma, pulmonary fibrosis) globally | ~20% | Global | Long-term | [4] |

### Technological Advancements in Automated Breathing Devices

With an estimated 30% of the total CAGR impact, technological innovation is the market's most significant development driver for oxygen treatment and respiratory care equipment. Clinical workflows are changing from reactive to predictive respiratory care as a result of the incorporation of artificial intelligence into respiratory device platforms, as seen by the 11.17% CAGR of AI-enabled technology. Healthcare institutions can now reduce capital expenditure per patient category by using smart ventilation systems like Getinge's Servo-c platform, which offers cross-population adaptability covering neonatal through adult care. With the help of advancements in battery technology, compact compressor design, and real-time SpO2 monitoring integration, portable oxygen concentrators and intelligent oxygen delivery systems (increasing at 14.67% CAGR) are facilitating a transition from institutional to ambulatory care settings.

The commercial impact of these innovations is amplified by their alignment with payer preferences for home-based care models that reduce hospital readmission rates and total cost of care. CPAP/BiPAP devices, growing at 8.25% CAGR, exemplify this trend as improved device comfort, noise reduction, and cloud-based adherence tracking have significantly expanded the addressable patient population for obstructive sleep apnea therapy [[6]](https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-medical-devices).

### Aging Population Increasing Demand for Long-Term Oxygen Therapy and Home Respiratory Care

The second most significant driver, accounting for about 28% of the CAGR acceleration, is demographic aging. By 2050, there will be more than 1.6 billion people over the age of 65 worldwide, with North America, Europe, and Japan experiencing the fastest increases [[11]](https://population.un.org/wpp). The frequency of COPD, lung fibrosis, and respiratory muscle weakening is disproportionately higher in the elderly, which creates a persistent need for long-term oxygen therapy. This generational transition is directly reflected in the [home healthcare](https://www.marketresearchfuture.com/reports/home-healthcare-market-2030) end-user market, which was valued at USD 7,489.43 million in 2025 and is expanding at a 7.99% CAGR. With a 9.58% CAGR, long-term care institutions are the end-user group with the quickest rate of growth, suggesting that both home care choices and institutional care models for elderly respiratory patients are developing.

### Growth in Hospital and Critical-Care Capacity

Hospital and ICU capacity expansion contributes an estimated 22% of the market's growth momentum. Hospitals remain the dominant end-user segment at USD 18,460.50 million in 2025, accounting for nearly half of total market revenue. In Asia-Pacific and Middle East & Africa, government-led investments in healthcare infrastructure are driving double-digit growth in ventilator installations and respiratory monitoring deployments [[9]](https://www.who.int/publications). Ventilators, valued at USD 4,240.81 million in 2025 with a 6.87% CAGR, continue to form a critical segment of institutional respiratory care procurement.

### Rising Prevalence of Respiratory Diseases

The escalating global burden of chronic respiratory diseases contributes approximately 20% to the overall CAGR. COPD alone accounts for USD 11,634.62 million in 2025 market demand, reflecting its status as the third leading cause of death globally. Asthma (USD 4,198.19 million), obstructive sleep apnea (USD 7,302.94 million), and pneumonia (USD 5,179.68 million) collectively sustain broad-based demand across all device categories. The rising incidence of pulmonary fibrosis (7.97% CAGR) and continued post-COVID respiratory complications further reinforce the structural demand foundation for the market [[4]](https://goldcopd.org).

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Drag on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Safety-related liabilities and stringent handling requirements for oxygen (fire hazard, transport, and storage controls) | ~35% | Global, acute in home settings | Ongoing | [12] |
| Strict regulatory requirements and approval timelines for automated breathing devices and monitoring accessories | ~40% | North America, Europe | Short-to-Medium-term | [13] |
| High upfront cost and reimbursement variability for home oxygen systems across countries | ~25% | Asia-Pacific, South America, Middle East & Africa | Medium-term | [14] |

### Safety-Related Liabilities and Stringent Handling Requirements for Oxygen

As an oxidant, oxygen poses a risk of fire and explosion during storage, transportation, and patient use. Strict handling procedures, such as pressure vessel certification, fire-resistant storage, and patient education requirements, are mandated by regulatory bodies. These safety restrictions limit the use of liquid oxygen systems in residential settings, increase operating costs for home oxygen providers, and expose device makers to liability. The drag effect, which partially offsets the rising momentum in the adoption of portable devices, is most noticeable in home healthcare and ambulatory settings where there is little professional monitoring [[12]](https://www.nfpa.org).

### Strict Regulatory Requirements and Approval Timelines

Medical device regulatory frameworks in the United States (FDA 510(k)/PMA), European Union (MDR 2017/745), and other major markets impose rigorous premarket approval processes for automated breathing devices and AI-enabled monitoring systems. Typical approval timelines range from 12 to 36 months, with additional post-market surveillance requirements. For emerging categories such as intelligent oxygen delivery systems and closed-loop ventilation platforms, the absence of established predicate devices can extend approval timelines further, delaying market entry and commercial revenue realization [[13]](https://www.fda.gov/medical-devices/premarket-submissions).

### High Upfront Cost and Reimbursement Variability

Home oxygen therapy systems, particularly advanced portable concentrators and AI-enabled devices, carry significant upfront capital costs ranging from USD 1,500 to USD 5,000 per unit at the consumer level. Reimbursement frameworks vary dramatically across countries: while Medicare in the United States and national health systems in Western Europe provide structured reimbursement pathways, coverage in emerging markets remains fragmented or absent. This cost barrier disproportionately constrains adoption in Asia-Pacific, South America, and Middle East & Africa, where out-of-pocket healthcare expenditure dominates [[14]](https://www.paho.org).

## Opportunities

## Oxygen Therapy and Respiratory Care Devices Market Opportunities

### Home and Ambulatory Oxygen Workflow Solutions (Remote Monitoring, Adherence Support, Telehealth Integration)

The convergence of oxygen therapy with digital health platforms represents a substantial market opportunity estimated to drive incremental revenue growth of 15–20% above baseline in the home healthcare segment by 2030. Remote patient monitoring systems that track oxygen flow rates, usage duration, and SpO2 levels in real time enable clinicians to intervene proactively, reducing emergency department visits and hospital readmissions. Adherence support platforms — incorporating mobile applications, automated refill scheduling, and caregiver alerts — address the well-documented challenge of patient non-compliance in long-term oxygen therapy. Telehealth integration further extends the value chain by enabling virtual respiratory assessments, device titration adjustments, and pulmonary rehabilitation coaching without in-person visits. The home healthcare end-user segment, already growing at 7.99% CAGR, stands to accelerate further as payers increasingly reimburse remote monitoring-enabled respiratory care models. Companies such as ResMed and Philips are positioning to capture this opportunity through cloud-connected device ecosystems [[8]](https://www.cms.gov).

### Long-Life, Low-Maintenance Oxygen Concentrators for Off-Grid and Low-Power Settings

Significant unmet demand exists for oxygen concentrators engineered for deployment in low-resource, off-grid, and unreliable-power environments — particularly in Sub-Saharan Africa, South Asia, and rural communities across emerging markets. The current generation of stationary oxygen concentrators typically requires stable 300–600W power supply and ambient operating temperatures below 40°C, limiting usability in tropical, rural, and disaster-relief contexts. Product innovations targeting solar-compatible power consumption (under 150W), extended sieve bed lifespans (exceeding 20,000 hours), and ruggedized enclosures for high-temperature and high-humidity environments could unlock a market segment estimated at USD 2–4 billion by 2035. The Middle East and Africa region, currently the smallest market at USD 1,337.76 million (2025) with a 5.59% CAGR, and South America at USD 1,695.54 million, represent the primary addressable geographies for this innovation category [[9]](https://www.who.int/publications).

## Future Outlook

## Oxygen Therapy and Respiratory Care Devices Market Future Outlook

### Technology and Product Evolution Trajectory

In the next ten years, intelligent, closed-loop respiratory management will replace passive oxygen delivery. Despite only being worth USD 79.73 million in 2025, intelligent oxygen delivery systems are expected to develop at the quickest rate of any device category, 14.67% CAGR, indicating a shift from clinician-titrated to algorithm-driven oxygen dosing. AI-enabled technology platforms (11.17% CAGR) will gradually incorporate computer vision for respiratory pattern detection, natural language processing for patient contact, and predictive analytics. A new class of "smart portable" devices that independently modify therapy in ambulatory settings will be made possible by the convergence of these capabilities with portable form factors, significantly increasing the treatable population beyond the confines of institutional care.

### Competitive Dynamics and Market Structure Evolution

The competitive landscape is moderately fragmented, with the top five players commanding approximately 33.7% combined market share and a substantial "Others" category at 66.3%. This structure suggests significant consolidation potential, particularly as technology differentiation increasingly determines market position. Companies with integrated hardware-software-cloud ecosystems (ResMed, Philips) are positioned to capture disproportionate value as recurring service revenue models supplement device sales. Strategic M&A activity is expected to accelerate, with established device manufacturers acquiring AI/digital health capabilities and technology companies entering the respiratory care space through partnerships or vertical integration.

### Digital, Regulatory, and Sustainability-Driven Shifts

Regulatory evolution will shape the market through two parallel forces: harmonization of medical device approval frameworks across major markets (reducing time-to-market for multinational companies) and increasing stringency for AI/ML-based device algorithms (requiring continuous real-world evidence generation). The EU MDR transition will continue to drive device portfolio rationalization among European manufacturers. Sustainability pressures — including medical waste reduction, energy-efficient concentrator design, and recyclable consumables — will emerge as competitive differentiators by 2030, particularly in European and North American procurement processes.

### Long-Range Demand Scenario

Demand fundamentals remain structurally positive through 2035. The global COPD patient population is projected to exceed 600 million by 2050 (WHO estimates), while obstructive sleep apnea diagnosis rates remain below 20% in most markets, representing a vast untapped patient pool. The expansion of health insurance coverage in emerging markets — particularly India, Indonesia, and Sub-Saharan Africa — will progressively convert latent demand into active device utilization. Under MRFR's base scenario, the market will approach USD 74.42 billion by 2035, with upside potential from accelerated AI adoption and downside risk from regulatory delays or macroeconomic-driven healthcare budget constraints.

## Segment Insights

## Oxygen Therapy and Respiratory Care Devices Market Segmentation

| Dimension | Sub-Segments | Dominant Segment (2025) | Fastest Growing Segment |
| --- | --- | --- | --- |
| Product | Oxygen Therapy Devices; Respiratory Care Devices; Consumables and Accessories | Respiratory Care Devices (USD 22,518.20 Mn) | Respiratory Care Devices (7.73% CAGR) |
| Type | Intelligent Oxygen Delivery Systems; Oxygen Concentrators; Compressed Oxygen Cylinders; Liquid Oxygen Systems; Oxygen Conserving Devices; Oxygen Flow Controllers; Ventilators; CPAP/BiPAP Devices; Nebulizers; Humidifiers; Respiratory Monitoring Devices; Airway Management Devices | Respiratory Monitoring Devices (USD 12,198.77 Mn) | Intelligent Oxygen Delivery Systems (14.67% CAGR) |
| Technology | Continuous Flow; Pulse Dose; Demand Flow; AI-enabled; Closed-loop; Others | Continuous Flow (USD 23,785.52 Mn) | AI-enabled (11.17% CAGR) |
| Device Portability | Stationary; Portable | Stationary (USD 22,802.62 Mn) | Portable (8.13% CAGR) |
| Indication | COPD; Asthma; OSA; Pneumonia; Pulmonary Fibrosis; ARDS/RDS; Cystic Fibrosis; Others | COPD (USD 11,634.62 Mn) | OSA (8.42% CAGR) |
| End User | Hospitals; Ambulatory Surgical Centers; Home Healthcare; Emergency Medical Facilities; Long-term Care Facilities; Other End Users | Hospitals (USD 18,460.50 Mn) | Long-term Care Facilities (9.58% CAGR) |

### By Product

| Segment | 2025 (USD Mn) | CAGR (2026–2035) | Primary Demand Driver |
| --- | --- | --- | --- |
| Oxygen Therapy Devices | 12,215.64 | 6.53% | COPD long-term therapy, home oxygen prescriptions |
| Respiratory Care Devices | 22,518.20 | 7.73% | Ventilator modernization, respiratory monitoring expansion |
| Consumables and Accessories | 2,834.84 | 3.69% | Recurring replacement demand, cannula/mask/tubing |

Respiratory care devices dominate the product landscape at USD 22,518.20 million, reflecting the breadth of ventilators, CPAP/BiPAP systems, monitoring devices, and airway management equipment within this category. The segment's 7.73% CAGR outpaces oxygen therapy devices (6.53%) due to technology-driven product refresh cycles in ventilation and monitoring platforms. Consumables and accessories, while the smallest segment, generate predictable recurring revenue streams anchored to the installed base of primary devices.

### By Type

| Segment | 2025 (USD Mn) | CAGR (2026–2035) | Primary Demand Driver |
| --- | --- | --- | --- |
| Intelligent Oxygen Delivery Systems | 79.73 | 14.67% | AI-driven titration, clinical outcome optimization |
| Oxygen Concentrators | 4,034.68 | 7.50% | Home oxygen therapy, portable device adoption |
| Compressed Oxygen Cylinders | 3,076.35 | 5.54% | Emergency and ambulatory oxygen supply |
| Liquid Oxygen Systems | 2,789.08 | 5.60% | High-flow institutional oxygen delivery |
| Oxygen Conserving Devices | 1,578.10 | 7.00% | Ambulatory patient oxygen economy |
| Oxygen Flow Controllers | 657.71 | 5.84% | Precision dosing in clinical settings |
| Ventilators | 4,240.81 | 6.87% | ICU capacity expansion, neonatal care |
| CPAP/BiPAP Devices | 2,193.05 | 8.25% | OSA diagnosis and treatment expansion |
| Nebulizers | 945.32 | 5.59% | Asthma and pediatric respiratory care |
| Humidifiers | 1,056.87 | 5.42% | Supplemental humidification for ventilated patients |
| Respiratory Monitoring Devices | 12,198.77 | 8.37% | Continuous SpO2/capnography monitoring |
| Airway Management Devices | 1,883.38 | 6.78% | Surgical and emergency airway intervention |

Respiratory monitoring devices represent the largest individual device type at USD 12,198.77 million, reflecting the clinical imperative for continuous respiratory parameter surveillance across ICU, step-down, and home settings. Intelligent oxygen delivery systems, while the smallest segment by 2025 revenue, exhibit the highest growth trajectory at 14.67% CAGR, driven by early-stage adoption of algorithm-driven oxygen titration in progressive healthcare systems. CPAP/BiPAP devices (8.25% CAGR) and respiratory monitoring devices (8.37% CAGR) round out the high-growth tier, propelled by expanding sleep apnea diagnosis rates and connected health monitoring adoption.

### By Technology

| Segment | 2025 (USD Mn) | CAGR (2026–2035) | Primary Demand Driver |
| --- | --- | --- | --- |
| Continuous Flow | 23,785.52 | 6.58% | Standard institutional and home oxygen delivery |
| Pulse Dose | 4,598.37 | 8.19% | Portable concentrator adoption, ambulatory care |
| Demand Flow | 3,246.74 | 5.12% | Oxygen conservation in mobile settings |
| AI-enabled | 2,762.60 | 11.17% | Predictive analytics, automated therapy adjustment |
| Closed-loop | 1,010.99 | 9.56% | Autonomous ventilation, neonatal ICU |
| Others | 2,164.46 | 4.73% | Specialty and legacy systems |

Continuous flow technology dominates the market at USD 23,785.52 million, reflecting its universal applicability across institutional and home oxygen therapy settings. AI-enabled technology platforms represent the fastest-growing technology segment at 11.17% CAGR, driven by the integration of machine learning algorithms for real-time therapy optimization, predictive exacerbation detection, and automated device parameter adjustment. Closed-loop technology (9.56% CAGR) is closely aligned with advanced ventilator systems that autonomously adjust respiratory support based on patient physiological parameters.

### By Device Portability

| Segment | 2025 (USD Mn) | CAGR (2026–2035) | Primary Demand Driver |
| --- | --- | --- | --- |
| Stationary | 22,802.62 | 6.35% | Hospital and long-term care institutional demand |
| Portable | 14,766.06 | 8.13% | Home care mobility, ambulatory patient independence |

Stationary devices account for the majority of market revenue at USD 22,802.62 million, anchored by hospital ventilators, stationary oxygen concentrators, and fixed monitoring systems. Portable devices, however, are growing significantly faster at 8.13% CAGR, reflecting the secular shift toward ambulatory care, patient empowerment, and home-based respiratory therapy. Battery technology improvements, weight reduction, and noise minimization are key enablers of portable device market expansion.

### By Indication

| Segment | 2025 (USD Mn) | CAGR (2026–2035) | Primary Demand Driver |
| --- | --- | --- | --- |
| COPD | 11,634.62 | 7.24% | High global prevalence, long-term therapy requirement |
| Asthma | 4,198.19 | 5.97% | Pediatric and adult nebulizer/inhaler demand |
| OSA | 7,302.94 | 8.42% | Rising diagnosis rates, CPAP device adoption |
| Pneumonia | 5,179.68 | 6.48% | Acute hospital oxygen demand, pediatric cases |
| Pulmonary Fibrosis | 2,214.65 | 7.97% | Progressive disease requiring escalating oxygen support |
| ARDS/RDS | 3,106.19 | 6.77% | Critical care ventilation, neonatal respiratory distress |
| Cystic Fibrosis | 943.19 | 5.08% | Chronic airway clearance and oxygen supplementation |
| Others | 2,989.23 | 5.65% | Post-surgical, trauma, and other respiratory support |

COPD is the dominant therapeutic indication at USD 11,634.62 million, consistent with its status as a leading cause of morbidity and mortality globally, requiring long-term oxygen therapy for millions of patients. Obstructive sleep apnea (OSA) is the fastest-growing indication at 8.42% CAGR, driven by increasing awareness, improved diagnostic screening, and expanding CPAP/BiPAP device access. Pulmonary fibrosis (7.97% CAGR) reflects the progressive, oxygen-dependent nature of the disease and the absence of curative therapies.

### By End User

| Segment | 2025 (USD Mn) | CAGR (2026–2035) | Primary Demand Driver |
| --- | --- | --- | --- |
| Hospitals | 18,460.50 | 7.06% | Acute care, ICU ventilation, surgical respiratory support |
| Ambulatory Surgical Centers | 3,897.74 | 4.84% | Procedure-linked oxygen supplementation |
| Home Healthcare | 7,489.43 | 7.99% | Aging population, portable device adoption, telehealth |
| Emergency Medical Facilities | 2,544.89 | 5.68% | First-response oxygen delivery, trauma care |
| Long-term Care Facilities | 3,251.70 | 9.58% | Elderly respiratory care, chronic disease management |
| Other End Users | 1,924.44 | 4.44% | Military, industrial, and specialty applications |

Hospitals remain the dominant end-user setting at USD 18,460.50 million, driven by the concentration of acute respiratory care, ventilator utilization, and advanced monitoring within institutional settings. Long-term care facilities are the fastest-growing end-user segment at 9.58% CAGR, directly reflecting the global demographic aging trend and the expansion of specialized respiratory care capacity within nursing and assisted living facilities. Home healthcare (7.99% CAGR) is the second-fastest growing segment, propelled by patient preference for home-based therapy, portable device technology improvements, and payer incentives for cost-effective care delivery models.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | 2025 Market (USD Mn) | CAGR (2026–2035) | Primary Investment Themes |
| --- | --- | --- | --- |
| North America | 15,263.19 | 6.05% | Home oxygen therapy, AI-enabled devices, telehealth integration |
| Europe | 11,498.64 | 7.28% | Ventilator platform modernization, long-term care, MDR compliance |
| Asia-Pacific | 7,773.56 | 9.21% | Hospital infrastructure expansion, portable concentrators, insurance coverage |
| South America | 1,695.54 | 4.84% | Public hospital oxygen supply, basic concentrator access |
| Middle East and Africa | 1,337.76 | 5.59% | Off-grid oxygen solutions, ICU capacity building, pandemic preparedness |
| Total | 37,568.69 | 7.09% | — |

### North America

| Country/Sub-Region | Key Metric | Key Driver |
| --- | --- | --- |
| United States | Largest national market globally | Medicare reimbursement framework, aging baby boomer cohort |
| Canada | Significant home care adoption | Provincial health system investment in respiratory care |

North America commands the largest regional revenue at USD 15,263.19 million in 2025, driven by the United States' extensive healthcare infrastructure, robust Medicare reimbursement for home oxygen therapy, and rapid adoption of AI-enabled respiratory monitoring platforms. The region's 6.05% CAGR reflects a mature but steadily expanding market where growth is primarily driven by product innovation (intelligent delivery systems, connected CPAP devices) and the demographic shift of the baby boomer generation into age cohorts with elevated respiratory disease prevalence. Inogen's launch of the Voxi 5 stationary concentrator specifically targeted the U.S. long-term care market, illustrating the commercial focus on this demographic.

### Europe

| Country/Sub-Region | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | Leading market by revenue | Strong MedTech manufacturing base, Drägerwerk leadership |
| France | Major acute care market | Public hospital modernization programs |
| United Kingdom | Growing home care segment | NHS Long Term Plan respiratory care investment |
| Italy | Significant elderly population | High COPD prevalence among aging demographics |

Europe is the dominant region by 2025 revenue share with USD 11,498.64 million, reflecting the continent's mature healthcare systems, comprehensive reimbursement structures, and established medical device manufacturing ecosystem. The 7.28% CAGR is supported by EU Medical Device Regulation (MDR 2017/745) compliance-driven product refresh cycles, increasing long-term care facility capacity, and strong adoption of advanced ventilator platforms. Germany anchors the region through companies like Drägerwerk AG and a well-developed respiratory care distribution infrastructure [[10]](https://ec.europa.eu/health/md_sector/new_regulations).

### Asia-Pacific

| Country/Sub-Region | Key Metric | Key Driver |
| --- | --- | --- |
| China | Fastest-growing major national market | Government healthcare infrastructure investment, pollution-related respiratory disease |
| India | High unmet demand | Growing insurance penetration, urbanization-linked asthma and COPD burden |
| Japan | Aging population driver | Highest elderly population share globally, advanced home care adoption |
| Australia | Mature market segment | Strong clinical practice standards for oxygen therapy |

Asia-Pacific is the fastest-growing region at 9.21% CAGR with a 2025 market size of USD 7,773.56 million. Growth is fueled by massive healthcare infrastructure investments in China and India, rising urban air pollution-linked respiratory disease prevalence, and expanding health insurance coverage that is bringing oxygen therapy within reach of broader patient populations. Japan's hyper-aged demographic profile drives disproportionate demand for home oxygen therapy and long-term respiratory care within the region [[9]](https://www.who.int/publications).

### South America

| Country/Sub-Region | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | Regional market leader | Public health system (SUS) oxygen procurement, urban hospital expansion |
| Argentina | Emerging market | Growing private healthcare sector investment |
| Colombia | Developing infrastructure | Government respiratory disease prevention programs |

South America accounts for USD 1,695.54 million in 2025, growing at 4.84% CAGR. Market expansion is constrained by fragmented reimbursement systems and limited home care infrastructure, but supported by Brazilian public health system procurement programs and increasing private-sector healthcare investment across the region. Oxygen supply infrastructure for rural and remote communities remains a significant unmet need [[14]](https://www.paho.org).

### Middle East and Africa

| Country/Sub-Region | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | GCC market leader | Vision 2030 healthcare investment, hospital capacity expansion |
| UAE | Advanced healthcare hub | Medical tourism, private hospital growth |
| South Africa | Sub-Saharan Africa leader | Post-COVID respiratory care infrastructure investment |

The Middle East and Africa region is the smallest at USD 1,337.76 million in 2025 but growing at 5.59% CAGR. Gulf Cooperation Council (GCC) states are driving growth through large-scale hospital construction and healthcare modernization programs, while Sub-Saharan Africa presents a significant opportunity for low-cost, off-grid oxygen concentrator deployment. COVID-19 exposed critical oxygen supply gaps across the African continent, catalyzing WHO-supported investments in medical oxygen infrastructure that will sustain long-term market growth [[9]](https://www.who.int/publications).

## Competitive Benchmarking

## Competitive Benchmarking

The global oxygen therapy and respiratory care devices market is moderately fragmented, with the top five companies collectively accounting for approximately 33.7% of total market revenue in 2025. The Herfindahl-Hirschman Index (HHI) for the top-tier segment is estimated in the low-to-moderate concentration range (approximately 250–350), indicating a competitive environment where no single player exercises dominant pricing power but established multinationals maintain significant technology and distribution advantages over smaller entrants. The remaining 66.3% market share is distributed among dozens of regional manufacturers, specialty device companies, and emerging technology firms, creating a dynamic competitive environment with significant M&A and partnership activity.

| Company | Est. Revenue Share | Key Offerings | Strategic Positioning |
| --- | --- | --- | --- |
| ResMed | 9.5% | CPAP/BiPAP systems, cloud-connected respiratory devices, digital health platforms | Market leader in sleep-disordered breathing and connected care ecosystems |
| Koninklijke Philips N.V. | 7.6% | Ventilators, oxygen concentrators, patient monitoring, sleep therapy devices | Integrated health technology provider with broad respiratory portfolio |
| Medtronic | 7.3% | Ventilators, airway management, respiratory monitoring, pulse oximetry | Diversified MedTech leader with respiratory care as strategic growth vertical |
| GE Healthcare | 4.7% | Patient monitoring systems, anesthesia delivery, respiratory diagnostics | Enterprise-scale hospital solutions with respiratory monitoring integration |
| Drägerwerk AG & Co. KGaA | 4.6% | Ventilators, anesthesia workstations, gas management, neonatal care devices | Premium critical care focus with strong European institutional relationships |
| Getinge | — | Servo-c ventilator platform, cardiac/surgical/ICU workflows | Clinical ventilation specialist with cross-age-group platform strategy |
| Inogen, Inc. | — | Portable and stationary oxygen concentrators | Pure-play oxygen therapy with direct-to-consumer distribution model |
| CAIRE Inc. | — | Stationary and portable oxygen concentrators, liquid oxygen systems | Oxygen therapy specialist serving home care and institutional markets |
| Dynasthetics, Inc. | — | Blended oxygen delivery, humidification systems | Niche specialty in anesthesia and perioperative respiratory care |
| Precision Medical Inc. | — | Oxygen regulators, flow meters, suction devices, respiratory accessories | Precision-engineered respiratory accessories and components supplier |
| Other Market Players | 66.3% | Regional manufacturers, digital health startups, consumable suppliers | Fragmented competition with technology-driven consolidation potential |

## Recent News & Developments

## Recent News & Developments

### Getinge (June 2025):

Getinge announced the expansion of its Servo-c ventilator portfolio with the introduction of a neonatal option, enabling the system to provide respiratory support across all patient groups from premature newborns to adult patients. This development is commercially significant as it transforms the Servo-c from a primarily adult/pediatric ventilator into a universal platform, reducing the need for hospitals to procure separate neonatal ventilation systems. The cross-population versatility lowers per-patient capital expenditure for healthcare facilities while strengthening Getinge's competitive position against Drägerwerk and Medtronic in the critical care ventilator segment. The intuitive interface and modern design of the Servo-c platform had already established strong market acceptance, and the neonatal extension broadens the addressable market to include neonatal intensive care units (NICUs) globally.

### Inogen, Inc. (June 2025):

Inogen announced the launch of the Voxi 5, a new stationary oxygen concentrator (SOC) developed to improve access to high-quality oxygen therapy for long-term care patients across the United States. This launch reinforces Inogen's strategic pivot from a portable concentrator specialist to a comprehensive home oxygen therapy provider. The Voxi 5 targets the stationary device segment (USD 22,802.62 million in 2025), positioning Inogen to capture share in the faster-growing long-term care facility end-user segment (9.58% CAGR). By addressing the stationary oxygen concentrator market, Inogen diversifies its revenue base and strengthens its value proposition for durable medical equipment (DME) providers seeking a single-source oxygen therapy partner.

### Getinge (January 2023):

In an earlier milestone, Getinge expanded its Servo-c ventilator portfolio by introducing a neonatal option, extending the system's capabilities to support patients of all ages, from premature infants to adults. Renowned for its clinical versatility and intuitive user interface, the Servo-c now offers a comprehensive ventilation solution across diverse healthcare settings, enabling clinicians to deliver consistent, high-quality ventilation for neonatal, pediatric, and adult patients using a single unified platform. This development laid the groundwork for the broader commercial expansion announced in 2025, signaling Getinge's long-term commitment to cross-population ventilator platform leadership.

## Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Oxygen Therapy and Respiratory Care Devices Market |
| Study Period | 2019–2035 |
| CAGR Window | 2026–2035 |
| Base Year | 2025 |
| Market Size (2025) | USD 37.57 Billion |
| Market Size (2035) | USD 74.42 Billion |
| CAGR (2026–2035) | 7.09% |
| Fastest Growing Region | North America (6.05% CAGR); Asia-Pacific highest regional CAGR at 9.21% |
| Dominant Region | Europe (USD 11,498.64 Million, 2025) |
| Fastest Growing Product | Respiratory Care Devices (7.73% CAGR) |
| Fastest Growing Type | Intelligent Oxygen Delivery Systems (14.67% CAGR) |
| Fastest Growing Technology | AI-enabled (11.17% CAGR) |
| Fastest Growing Device Portability | Portable (8.13% CAGR) |
| Fastest Growing Indication | Obstructive Sleep Apnea (8.42% CAGR) |
| Fastest Growing End User | Long-term Care Facilities (9.58% CAGR) |
| Companies Profiled | ResMed; Koninklijke Philips N.V.; Medtronic; GE Healthcare; Drägerwerk AG & Co. KGaA; Getinge; Inogen, Inc.; CAIRE Inc.; Dynasthetics, Inc.; Precision Medical Inc. |
| Valuation Currency | USD (Million for segment data; Billion for headline figures) |
| Segments Covered | Product, Type, Technology, Device Portability, Indication, End User, Region |

## Frequently Asked Questions

**Q: What is the projected global market size for oxygen therapy and respiratory care devices by 2035?**
A: The global oxygen therapy and respiratory care devices market is projected to reach USD 74.42 billion by 2035, growing from USD 37.57 billion in 2025 at a CAGR of 7.09% during the 2026–2035 forecast period. This near-doubling of market size is driven by structural demand from aging populations, rising chronic respiratory disease prevalence, and technology-driven product innovation across all device categories.

**Q: Which device type is expected to grow the fastest during the forecast period?**
A: Intelligent oxygen delivery systems are projected to be the fastest-growing device type with a CAGR of 14.67% during 2026–2035. Although currently a small segment at USD 79.73 million in 2025, these AI-driven systems represent a paradigm shift toward automated, closed-loop oxygen titration that optimizes clinical outcomes while reducing clinician workload. AI-enabled technology platforms more broadly are growing at 11.17% CAGR.

**Q: Which region dominates the market and which is growing fastest?**
A: Europe is the dominant region by 2025 revenue with USD 11,498.64 million, supported by mature healthcare systems and comprehensive reimbursement frameworks. Asia-Pacific is the fastest-growing region at 9.21% CAGR, driven by healthcare infrastructure expansion in China and India, rising respiratory disease burden, and expanding insurance coverage. North America leads in absolute revenue at USD 15,263.19 million.

**Q: How are competitive dynamics expected to evolve in this market?**
A: The market is moderately fragmented with the top five players (ResMed, Philips, Medtronic, GE Healthcare, Drägerwerk) holding approximately 33.7% combined share. Consolidation is expected to accelerate as technology differentiation — particularly in AI-enabled devices and connected care platforms — becomes a decisive competitive factor. Companies with integrated hardware-software-cloud ecosystems are positioned to capture disproportionate value through recurring service revenue models.

**Q: What is driving the shift from stationary to portable respiratory devices?**
A: The portable device segment is growing at 8.13% CAGR compared to 6.35% for stationary devices, driven by patient preference for mobility and independence, improvements in battery technology and compressor miniaturization, expanding home healthcare delivery models (7.99% CAGR), and payer incentives for cost-effective outpatient care. Inogen's launch of the Voxi 5 and similar product innovations exemplify the industry's strategic focus on portable and home-use form factors.

**Q: What role does obstructive sleep apnea play in market growth?**
A: Obstructive sleep apnea (OSA) is the fastest-growing therapeutic indication at 8.42% CAGR, with a 2025 market size of USD 7,302.94 million. The segment's growth reflects increasing diagnosis rates (current diagnostic penetration is estimated below 20% globally), growing awareness of cardiovascular comorbidity risks associated with untreated OSA, and improved CPAP/BiPAP device comfort and adherence-tracking technology. CPAP/BiPAP devices specifically are growing at 8.25% CAGR.

**Q: What are the primary barriers to market growth?**
A: Three key restraints constrain the market: strict regulatory approval timelines for automated breathing devices and AI-enabled monitoring systems (contributing approximately 40% of CAGR drag); safety-related liabilities and handling requirements for medical oxygen in home and transport settings (35% drag); and high upfront costs with variable reimbursement coverage for home oxygen systems across geographies (25% drag), particularly affecting adoption in emerging markets.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/oxygen-therapy-and-respiratory-care-devices-market-68396*